Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 0.67 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.62 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.62 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.54 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237183 | 1.00 | ITPR3 (0.67) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL220555 | 1.00 | ITPR3 (0.67) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL19712146 | 0.98 | ITPR3 (0.65) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL5176539 | 0.98 | ITPR3 (0.65) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL14992390 | 0.96 | ITPR3 (0.61) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL11233751 | 0.93 | ITPR3 (0.60) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL7171543 | 0.93 | ITPR3 (0.60) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL4343592 | 0.93 | ITPR3 (0.74) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL4343591 | 0.93 | ITPR3 (0.74) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL6664274 | 0.93 | ITPR3 (0.74) | ITPR3ITPR1ITPR2INPP5AINPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260767-B | Flame-retardant high-temperature vulcanized silicone rubber and preparation method thereof | 深圳市捷超行模具有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-112074276-A | Inositol-based immunotherapy | 诺姆奥克塞斯公司 | 2020-12-11 | — | — | CN | claimed |
| EP-2451459-B1 | METHOD OF REDUCING MULTI-DRUG RESISTANCE USING INOSITOL TRIPYROPHOSPHATE | NORMOXYS INC (US) | 2017-11-22 | — | — | EP | claimed |
| US-20160235771-A1 | METHOD OF REDUCING MULTI-DRUG RESISTANCE USING INOSITOL TRIPYROPHOSPHATE | NORMOXYS, INC. | 2016-08-18 | — | — | US | claimed |
| US-20160120887-A9 | TUMOR ERADICATION BY INOSITOL-TRIPYROPHOSPHATE | NORMOXYS, INC. (US) | 2016-05-05 | — | — | US | claimed |
| US-20160067267-A1 | MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT | NORMOXYS, INC. (US) | 2016-03-10 | — | — | US | claimed |
| EP-2968617-A1 | MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT | NormOxys, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| EP-1973398-B1 | USE OF INOSITOL-TRIPYROPHOSPHATE IN TREATING TUMORS MEDIATED BY ANGIOGENESIS | NORMOXYS INC (US) | 2016-01-06 | — | — | EP | claimed |
| WO-2014143939-A1 | MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT | NORMOXYS, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| US-20140194391-A1 | CALCIUM/SODIUM SALT OF INOSITOL TRIPYROPHOSPHATE AS AN ALLOSTERIC EFFECTOR OF HEMOGLOBIN | UNIVERSITE DE STRASBOURG (FR) | 2014-07-10 | — | — | US | claimed |
| WO-2007081315-A1 | USE OF INOSITOL-TRIPYROPHOSPHATE IN TREATING TUMORS AND DISEASES | OXYPLUS, INC. (US) | 2007-07-19 | — | — | WO | claimed |
| US-20070135389-A1 | calcium and sodium mixed salt of inositol tripyrophosphate; anticancer | NORMOXYS, INC. | 2007-06-14 | — | — | US | claimed |
| US-20060258626-A1 | Cancer, stroke, Alzheimer's, osteoporosis; angiogenesis inhibitor, antihypoxic agent | NORMOXYS, INC. | 2006-11-16 | — | — | US | claimed |
| US-20060241086-A1 | Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin | NORMOXYS, INC. | 2006-10-26 | — | — | US | claimed |
| WO-2006102060-A1 | CALCIUM SALT OF MYO-INOSITOL 1,6:2,3:4,5 TRIPYROPHOSPHATE AS AN ALLOSTERIC EFFECTOR OF HEMOGLOBIN | OXYPLUS, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060116358-A1 | Delivering modified inositol hexaphosphate (IHP); enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells; cardiovascular and respiratory disorders | NORMOXYS, INC. | 2006-06-01 | — | — | US | claimed |
| US-20060106000-A1 | Use of inositol-tripyrophosphate in treating tumors and diseases | NORMOXYS, INC. | 2006-05-18 | — | — | US | claimed |
| EP-1503768-A1 | INOSITOL PYROPHOSPHATES, AND METHODS OF USE THEREOF | GMP Oxycell, Inc. (US) | 2005-02-09 | — | — | EP | claimed |
| US-20040014642-A1 | Supplying oxygen to cells; antiischemic agents; cardiovascular disorders | NORMOXYS, INC. | 2004-01-22 | — | — | US | claimed |
| WO-2003092700-A1 | INOSITOL PYROPHOSPHATES, AND METHODS OF USE THEREOF | GMP OXYCELL, INC. (US) | 2003-11-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106000-A1 | Use of inositol-tripyrophosphate in treating tumors and diseases | PPIP5K2, ITPA, INPP5B | ITPR3 10/4885ITPR1 9/4885ITPR2 13/4885 |
| US-20060241086-A1 | Calcium salt of myo-inositol 1,6:2,3:4,5 tripyrophosphate as an allosteric effector of hemoglobin | ITPR3, ITPR1, ITPR2 | ITPR3 1/4885ITPR1 2/4885ITPR2 3/4885 |
| US-20040014642-A1 | Supplying oxygen to cells; antiischemic agents; cardiovascular disorders | PPIP5K2, ITPA, DHPS | ITPR3 30/4885ITPR1 22/4885ITPR2 24/4885 |
| US-20060116358-A1 | Delivering modified inositol hexaphosphate (IHP); enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells; cardiovascular and respiratory disorders | PPIP5K2, ITPA, INPP5B | ITPR3 10/4885ITPR1 9/4885ITPR2 15/4885 |
| US-20060258626-A1 | Cancer, stroke, Alzheimer's, osteoporosis; angiogenesis inhibitor, antihypoxic agent | HIF1AN, GPR119, IGF1R | ITPR3 35/4885ITPR1 25/4885ITPR2 36/4885 |
| US-20160120887-A9 | TUMOR ERADICATION BY INOSITOL-TRIPYROPHOSPHATE | PPIP5K2, ITPR3, ITPR1 | ITPR3 2/4885ITPR1 3/4885ITPR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.